Join the club for FREE to access the whole archive and other member benefits.

Cyclarity Therapeutics

Company developing simple and direct interventions targeting toxic forms of cholesterol for age-related diseases

Cyclarity develops easy-to-use drugs that prevent common age-related conditions such as atherosclerosis, heart-attack and stroke by addressing the root cause - a build-up of arterial plaque.

The company's technology removes arterial plaque by clearing the non-degradable cholesterol that accumulates within cells in the arterial walls.

Previously called Underdog Pharmaceuticals, the company changed its name in 2022.

Underdog was built from an SRF flagship program that has driven two years of applied development designed to explore and repair the underlying causes of cardiovascular disease. Its co-founders are Matthew O’Connor, Ph.D., and Michael Kope, formerly the Vice President of Research and the founding Chief Executive Officer, respectively, of SRF. 

Hoping to start clinical trials in the UK in 2023.

Cyclarity Therapeutics Executive Team

  • Matthew ‘Oki’ O’Connor, CEO of Scientific Affairs
  • Michael Kope, CEO of Corporate Affairs

Cyclarity Therapeutics Staff

  • Daniel M. Clemens, Vice President of Biology
  • Noah Rosenberg, Head of Clinical Affairs
  • Keivan Sadrerafi, Director of Chemistry
  • Amelia Anderson, Head of Scientific Computing & Co-Founder

Visit website:




See also: Institute SENS Research Foundation - Non-profit organization focused on transforming the way the world researches and treats age-related diseases

Details last updated 03-Feb-2020

Mentioned in this Resource

Amelia Anderson

Head of Scientific Computing & Co-Founder at Cyclarity Therapeutics

Daniel Clemens

Vice President of Biology at Cyclarity Therapeutics

Keivan Sadrerafi

Director of Chemistry at Cyclarity Therapeutics

Matthew O’Connor

Co-Chief Executive Officer and Co-founder of Cyclarity Therapeutics (former Underdog Pharmaceuticals)

Michael Kope

Co-Chief Executive Officer and Co-founder Underdog Pharmaceuticals

Noah Rosenberg

Head of Clinical Affairs at Cyclarity Therapeutics

Cyclarity Therapeutics News

Reason reports back from Rejuvenation Startup Summit 2024

Fight Aging! - 13-May-2024

A great summary of 25 speakers who are in various stages of platform building, drug discovery and clinical trials

Read more... speaks to Cyclarity’s CEO for an update on its novel atherosclerosis treatment (LEAF) - 19-Feb-2024

The company is developing a drug called UDP-003 to treat the disease


Reason reports back from October's Rejuvenation Startup Summit

Fight Aging! - 19-Oct-2022

Some really exciting developments with quite a few in clinical trials


Racing for the lead... Underdog becomes Cyclarity Therapeutics

Longevity Technology - 20-Jun-2022

Also announces move to Buck Institute for Research on Aging


Underdog pharmaceuticals secures $10m funding from Kizoo ventures

Longevity Technology - 23-Sep-2021

Funds to bring affordable and effective age-related therapies to the public


'Innovation Passport' awarded for Underdog's novel compound intended for treating heart diseases

Longevity Technology - 09-Sep-2021

Safe and potential compound shows disease-modifying effect by removing toxic cholesterol from blood


Two drug molecules delivered via nanoparticles to combat atherosclerosis (LEAF) - 26-Jun-2020

Success in mice model gives hope for fighting cholesterol-associated inflammatory diseases


Fight Aging! reports back from SENS Research Foundation Pitch Day

Fight Aging! - 20-Jan-2020

When some of these succeed in human trials even more money will pile in to fund further advances

Topics mentioned on this page:
Ageing Research, Heart Disease